Cure My Disease

Don't miss your cure!

 Log in / Sign up

Less contrast, same clarity: new MRI method could reduce gadolinium exposure

NCT ID NCT04113395

Diagnosis Sponsor: Fondation Ophtalmologique Adolphe de Rothschild Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looked at whether using a much lower dose of gadolinium (a contrast dye) in MRI scans can still find meningiomas (a type of brain tumor) as well as the standard full dose. Over 500 adults getting a brain MRI for screening or follow-up took part. The goal is to reduce the amount of gadolinium patients receive, which can build up in the body over time.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

514 people

The number who actually took part.

Started

Dec 2019

Finished

Jul 2025

Lead sponsor

A research network

The lead sponsor is a research network or cooperative group.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Patients presenting to the radiology department of the Adolphe de Rothschild Foundation for an MRI, as part of a screening or monitoring of meningioma

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patient over 18 years of age * Patient performing MRI as part of a screening or follow-up of known meningioma * Express consent to participate in the study Exclusion Criteria: * Contraindication for MRI (electrical device, metallic foreign body, claustrophobia) * Known hypersensitivity to the contrast medium (Gadolinium) * Known renal failure: glomerular filtration rate \<30mL/min * Patient benefiting from a legal protection measure * Pregnant or breastfeeding woman

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Meningioma are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

meningioma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Meningioma

Contacts and locations

Locations

  • CHU de Bordeaux

    Bordeaux, 33076, France

  • CHU de Grenoble

    Grenoble, Grenoble, 38100, France

  • CHU de Limoges

    Limoges, Limoges, 87042, France

  • CHU de Lyon

    Lyon, Lyon, 69495, France

  • CHU de Nantes

    Nantes, Nantes, 44800, France

  • CHU de Rennes

    Rennes, Rennes, 35033, France

  • CHU de Rouen

    Rouen, Rouen, 76000, France

  • CHU de Strasbourg

    Strasbourg, Strasbourg, 67000, France

  • CHU de Tours

    Tours, Tours, France

  • Fondation ophtalmique Adolphe de Rothschild

    Paris, Paris, 75019, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.